Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05505565 · ClinicalTrials.gov registry record · NA
Tolerability, Acceptance, and Utility of Intermittent CGM Use in Youth With Prediabetes
A NA study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 54
- Enrollment target
NCT05505565: Completed NA study, sponsored by University of Alabama at Birmingham.
NCT05505565 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 54 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05505565, a NA study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
Study Summary
We are evaluating whether intermittent use of continuous glucose monitors (CGMs) in addition to standard nutritional counseling and physical activity counseling is associated with improved metabolic health for youth with pre-diabetes (PD).
Primary Outcome
Caregiver and patient acceptability of CGM use
Interventions
- DEVICE Abbott Freestyle Libre 2
- OTHER Standard physical activity and nutritional counseling for prediabetes management
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2023-06-05 |
| Est. Completion | 2025-05-15 |
| Phase | NA |
What the finished NCT05505565 record still lists
NCT05505565 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Abbott Freestyle Libre 2 is the first listed.
NCT05505565 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05505565 about?
NCT05505565 is a clinical study titled "Tolerability, Acceptance, and Utility of Intermittent CGM Use in Youth With Prediabetes". We are evaluating whether intermittent use of continuous glucose monitors (CGMs) in addition to standard nutritional counseling and physical activity counseling is associated with improved metabolic health for youth with pre-diabetes (PD).
What is the current status of trial NCT05505565?
This trial is currently completed. It is a NA study. The enrollment target is 54 participants. The study started on 2023-06-05. Estimated completion is 2025-05-15.
What interventions are being tested in trial NCT05505565?
The interventions under investigation include: Abbott Freestyle Libre 2 (DEVICE), Standard physical activity and nutritional counseling for prediabetes management (OTHER).
Who is sponsoring clinical trial NCT05505565?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05505565's enrollment target sits among peer trials
54 1268th of 2000 higher than 730 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI